Prosecution Insights
Last updated: April 19, 2026
Application No. 19/045,608

WOUND CARE IMAGE ANALYSIS USING A SMARTPHONE

Non-Final OA §102§103
Filed
Feb 05, 2025
Examiner
CATTUNGAL, SANJAY
Art Unit
3798
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Precision Healing, LLC
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
3y 3m
To Grant
94%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
850 granted / 1024 resolved
+13.0% vs TC avg
Moderate +12% lift
Without
With
+11.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
28 currently pending
Career history
1052
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
38.7%
-1.3% vs TC avg
§112
7.2%
-32.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1024 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-4, 6-20, and 22-24 is/are rejected under 35 U.S.C. 102a1/a2 as being anticipated by U. S. Patent No. 10,438,356 to Dacosta. Regarding Claim 1, 23, and 24, Dacosta teaches a method, system and program for image analysis comprising: obtaining access to a smartphone, wherein the smartphone includes an integrated color camera (fig. 6a teaches a smartphone camera); coupling an external light source to the smartphone, wherein the external light source emits at least one light wavelength capable of illuminating a material sample, wherein the at least one light wavelength excites a fluorescence response from the material sample, and wherein the fluorescence response comprises wavelengths along the Red-Green-Blue (RGB) light wavelength spectrum (col. 17 lines 1-32 teaches RGB excitation wavelength light); triggering the external light source (col. 17 lines 1-32 teaches multiple excitation wavelength light); capturing an illumination signature of the material sample, by the integrated color camera, in response to the external light source that was triggered (fig. 6a teaches external light source connected to smartphone and col. 17 lines 1-32 teaches multiple excitation wavelength light); and generating an output indicative of biophysical status of the material sample, wherein the output is based on analysis of the illumination signature that was captured (col. 2 lines 7-55 and fig. 7a and 7b teaches generating an output based on analysis). Regarding Claim 2, Dacosta teaches comprising augmenting the analysis of the illumination signature using depth-sensing technology integrated within the smartphone (col. 14 line 10-30 teaches depth sensing technology). Regarding Claim 3, Dacosta teaches that the depth-sensing technology comprises a component of a smartphone camera system (fig. 1 and ocl. 14 lines 10-30 teaches smartphone with depth sensing technology). Regarding Claim 4, Dacosta teaches that the depth-sensing technology enables correction of the biophysical status due to inverse square law energy falloff of the fluorescence response (col. 11 line 50 through col. 12 line 45 teaches correcting distance between imaging device and target). Regarding Claim 6, Dacosta teaches that the capturing an illumination signature is initiated using wireless communication between the external light source and the smartphone (fig. 6a and fig. 38 teaches external light source). Regarding Claim 7, Dacosta teaches that the capturing an illumination signature is initiated using a bar code reader by a sensor coupled to the external light source (fig. 26 teaches bar code for illumination signature). Regarding Claim 8, Dacosta teaches that the material sample comprises an in situ skin wound (col. 39 lines 51-65 teaches skin wound analysis). Regarding Claim 9 and 10, Dacosta teaches an additional output for a material sample comprising the biochemical assay of wound analytes is analyzed in conjunction with the output indicative of biophysical status of the material sample (col. 36 lines 26-33 teaches biochemical assay for wound analyte analysis). Regarding Claim 11, Dacosta teaches that the external light source emits at least one additional light wavelength to illuminate the material sample (col. 17 lines 1-32 teaches multiple excitation wavelength light). Regarding Claim 12, Dacosta teaches that the at least one additional light wavelength is used to capture an absorption response of the material sample (col. 17 lines 1-32 teaches multiple excitation wavelength light). Regarding Claim 13, Dacosta teaches comprising augmenting the output, based on an analysis of the absorption response (col. 26 lines 54-65 teaches analysis of absorption response). Regarding Claim 14, Dacosta teaches the at least one additional light wavelength comprises three additional light wavelengths comprising a blue-band light wavelength, a green-band light wavelength, and a red-band light wavelength (col. 17 lines 1-32 teaches red, blue, green wavelength). Regarding Claim 15, Dacosta teaches that the external light source emits at least one further additional light wavelength, wherein the at least one further additional light wavelength comprises an infrared-band light wavelength (col. 17 lines 1-32 teaches infrared excitation light). Regarding Claim 16, Dacosta teaches triggering, the capturing, and/or the generating are performed by an app loaded on the smartphone (col. 40 lines 1-35 teaches an app on smartphone to trigger, capture and generating image). Regarding Claim 17, Dacosta teaches triggering, the capturing, and/or the generating are initiated externally to the smartphone (col. 40 lines 1-35 teaches remote trigger, capture and generating image). Regarding Claim 18, Dacosta teaches capturing a thermal image of the material sample using an infrared sensor coupled to the external light source (col. 12 lines 1-5 teaches infrared sensors). Regarding Claim 19, Dacosta teaches augmenting the output, based on an analysis of the thermal image (col. 32 lines 2-20 teaches thermal image). Regarding Claim 21, Dacosta teaches that the at least one light wavelength that excites fluorescence characteristics of the material sample is substantially a 405nm light wavelength (col. 17 lines 1-32 teaches 405nm excitation light). Regarding Claim 22, Dacosta teaches that the additional light wavelength enables differentiation between the presence of reduced nicotinamide adenine dinucleotide (NADH) and connective tissue (col. 26 lines 54-65 teaches NADH and connective tissue imaging). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 5 is/are rejected under 35 U.S.C. 103 as being unpatentable over U. S. Patent No. 10,438,356 to Dacosta in view of U. S. Publication No. 2021/0012172 to Beitel. Regarding Claim 5, Dacosta teaches all of the above claimed limitations but does not expressly teach capturing an illumination signature is initiated by a series of flashes from the external light source. Beitel teaches capturing an illumination signature is initiated by a series of flashes from the external light source (para 0053). It would be obvious to one of ordinary skill in the art at the time of filing to modify Dacost with capturing an illumination signature initiated with a series of flashes as taught by Beitel, since such a setup would result in more uniform imaging as illumination signature is captured resulting in the imaging being consistent as its calibrated. Claim(s) 21 is/are rejected under 35 U.S.C. 103 as being unpatentable over U. S. Patent No. 10,438,356 to Dacosta in view of U. S. Publication No. 2024/0027417 to Vasefi et al. Regarding Claim 21 Dacosta teaches all of the above claimed limitations but does not expressly teach comprising adding an additional light wavelength to adjust the illumination signature, wherein the additional light wavelength is substantially a 365nm light wavelength (para 0127, 0137, 0166, and 0209 teaches 365nm light wavelength). Vasefi teaches comprising adding an additional light wavelength to adjust the illumination signature, wherein the additional light wavelength is substantially a 365nm light wavelength (para 0127, 0137, 0166, and 0209 teaches 365nm light wavelength). It would be obvious to one of ordinary skill in the art at the time of filing to modify Dacosta with an additional wavelength of 365 nm as taught by Vasefi, since uv light would result in fluorescence imaging, which would yield a predictable result of analyzing wounds healing in a subject. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SANJAY CATTUNGAL whose telephone number is (571)272-1306. The examiner can normally be reached M-F 9-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Keith Raymond can be reached at 571-270-1790. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SANJAY CATTUNGAL/Primary Examiner, Art Unit 3798
Read full office action

Prosecution Timeline

Feb 05, 2025
Application Filed
Mar 21, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12588893
TABLET ULTRASOUND SYSTEM
2y 5m to grant Granted Mar 31, 2026
Patent 12582363
Mobile X-Ray Imaging System
2y 5m to grant Granted Mar 24, 2026
Patent 12582482
SYSTEMS AND METHODS FOR PREDICTING CORONARY PLAQUE VULNERABILITY FROM PATIENT-SPECIFIC ANATOMIC IMAGE DATA
2y 5m to grant Granted Mar 24, 2026
Patent 12582356
INTRAVASCULAR DEVICES, SYSTEMS, AND METHODS
2y 5m to grant Granted Mar 24, 2026
Patent 12575806
POWER REDUCTION OF FETAL ULTRASOUND TRANSDUCERS FOR EXTENDED BATTERY LIFE
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
94%
With Interview (+11.5%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 1024 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month